A newly published review in Genes & Diseases explores the oncogenic activation of PIK3CA in cancer and highlights emerging targeted therapies designed to improve treatment efficacy while reducing side ...
Finding showed the inavolisib-based regimen reduced the risk of disease progression or death by 57% compared with palbociclib and fulvestrant alone. The Food and Drug Administration (FDA) has approved ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted ...
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses the latest advancements in HR+/HER2– breast cancer research, as well as the ...
Hosted on MSN
A Promising New Option For PIK3CA-Mutated Breast Cancer: What New Data On Inavolisib Could Mean for You
Some breast cancers “feed” on the hormone estrogen. These are usually treated with medicines that either block estrogen’s signal (fulvestrant) or slow the cancer’s growth cycle (palbociclib). In about ...
– Approval is based on Phase III INAVO120 results, showing the Itovebi TM (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback